🟢 Humacyte is trading 5% up in pre-market as broader growth-stock demand lifted risk appetite

Humacyte is trading 5.09% up at $0.60 after broader growth-stock demand and firmer U.S. futures supported pre-market risk appetite on September 17, 2026.

• Major indexes were up more than 0.8% as investors assessed the Federal Reserve’s recent 25-basis-point hike.
• A September 16 H.C. Wainwright presentation outlined dialysis-access and coronary-bypass plans, but did not explicitly link that event to the share move.